Scalper1 News
Zynerba Pharmaceuticals (ZYNE) got a strong start on its first day of trading Wednesday, with an initial public offering that raised $42 million. Zynerba is developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. It’s looking to treat central nervous system disorders with treatments derived from cannabis. The company late Tuesday priced 3 million shares at 14, the midpoint of its expected Scalper1 News
Scalper1 News